Abstract: The present invention refers to a pharmaceutical composition suitable for the transdermal or transmucosal administration of one or more active agents, in form of a gel or a solution, comprising as a permeation enhancers a combination of: a) saturated fatty alcohol of formula CH3—(CH2)n—CH2OH or saturated fatty acid CH3—(CH2)n—CH2COOH wherein n is an integer number 8÷22, preferably 8÷12, most preferably 10, or unsaturated fatty alcohol or fatty acid of formula: CH3(CnH2(n-1))—OH or CH3(CnH2(n-1))—COOH wherein n is an integer number 8÷22, b) a ternary vehicle or carrier consisting of a C1÷C4 alkanol, a polyalcohol in particular propylenglycol and water, c) optionally also a monoalkylether of diethylenglycol.

Abstract: The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed.

Abstract: The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.

Abstract: Carriers for drug delivery, methods of making such carriers and for associating them to drugs, the resulting carrier and drug combination and methods for drug delivery, particularly controlled or sustained release delivery, using such carrier and drug combinations.

Abstract: A method for preparation of block copolymeric nanoparticles is disclosed. The method is a single-step preparation in which block copolymeric nanoparticles are produced directly from a solution of crosslinkable block copolymer in a carrier medium. The block copolymeric nanoparticles thus formed have at least one crosslinked polymeric phase.

Abstract: A cosmetic composition having improved transfer resistance comprising: a) from about 0.1–60% by weight of trimethylated silica, b) from about 0.1–60% by weight of a volatile solvent having a viscosity of 0.5 to 100 centipoise at 25° C., c) 0.1–60% by weight of a nonvolatile oil having a viscosity of 200 to 1,000,000 centipoise at 25° C. d) 0.1–80% of a cosmetically acceptable carrier.

Abstract: A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.

Abstract: The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an antifungal agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting antifungal agent to an animal which comprises applying an effective amount of the antifungal agent in the form of the drug delivery system of the present invention.

Abstract: Spinal anesthetics for intrathecal administration to produce spinal anesthesia are provided with use of 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue or its pharmaceutically active analogs.

Abstract: A system for delivering a chemical agent in the form of a spray or foam, which in a preferred embodiment involves the use of an aerosol dispenser to deliver a formulation containing both an anionic surface active agent such as sodium lauryl sulfate as a foaming agent and a chemical agent such as either hydrogen peroxide as a disinfecting chemical agent or natural sea water.

Abstract: The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8–C22 fatty acid, and preferably may be a saturated or unsaturated C10–C18 fatty acid. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer.

Abstract: Disclosed is a spherical powder component comprising: (1) a large spherical powder having a particle size of from about 10 ?m to about 50 ?m; and (2) a small spherical powder having a particle size of from about 1 ?m to about 10 ?m; wherein at least one of the large spherical powder and at least one of the small spherical powder are made of the same material, and the weight ratio of the large spherical powder to the small spherical powder is from about 25:1 to about 1:25.

Abstract: Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.

Abstract: This invention relates to new dermocosmetic and pharmaceutical compositions which are useful for improving and treating hyperreactive skin conditions and more generally allergic-type reactions and/or intolerance phenomena, whether they are caused by external factors or factors intrinsic to the individual. The compositions of this invention preferably contain an anti-radical, in anti-inflammatory and an anti-allergic activity for the treatment of sensitive and/or allergic skin.

Abstract: A medical composition for protuberance of epithelium, which comprises a solution comprising a polysaccharide or a medically acceptable salt thereof, wherein the solution has a viscosity of: (1) from 50 to 500 mPa·s at a shear rate of from 7.7 to 10.0 s?1; (2) from 45 to 300 mPa·s at a shear rate of from 19.2 to 20.0 s?1; and (3) from 40 to 200 mPa·s at a shear rate of from 38.3 to 40.0 s?1, when measured using a rotational viscometer at 25° C., and a syringe filled with the medical composition.

Abstract: A cosmetic composition having improved transfer resistance comprising: a) from about 0.1–60% by weight of trimethylated silica, b) from about 0.1–60% by weight of a volatile solvent having a viscosity of 0.5 to 100 centipoise at 25° C., c) 0.1–60% by weight of a nonvolatile oil having a viscosity of 200 to 1,000,000 centipoise at 25° C. d) 0.1–80% of a cosmetically acceptable carrier.

Abstract: The present invention relates to a film-forming barrier composition useful for protecting the skin from body fluids, such as urine, feces, menses. The composition comprises a skin conditioning agent, a viscosity enhancing agent and an oleophilic film-forming agent. Optionally, the lotion may comprise skin care ingredients for treating or maintaining skin health. The composition may be applied to the skin by suitable delivery vehicles, such as absorbent articles or components thereof, sheet materials, pads, bandages, sponges, foam pads, pumps, sprays, depending on the viscosity of the composition.

Abstract: The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an anti-alopecia agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting anti-alopecia agent to an animal which comprises applying an effective amount of the anti-alopecia agent in the form of the drug delivery system of the present invention.

Abstract: The present invention relates to an anhydrous liquid composition wherein monoglyceride is mixed with an emulsifier and a solvent, and the manufacturing method thereof, and more specifically, to an anhydrous liquid composition wherein monoglyceride is mixed with a water-insoluble material, an emulsifier and a solvent, and the manufacturing method thereof. Further, the present invention relates to a lyophilized powder and the manufacturing method thereof, wherein the lyophilized powder is prepared by dissolving the mixed liquid composition in water, adding with a cryoprotectant followed by the lyophilization. In the process of dispersion, the lyophilized liquid composition and the powder of the present invention can spontaneously generate particles of 200-500 nm by gently shaking with hands without a powerful mechanical force.

Abstract: The present invention provides methods of treating early morning pathologies using a time-specific controlled release dosage formulation which is administered prior to sleep, and which permits or achieves delivery of a pharmaceutically active agent effective for the treatment of the specific early morning pathology to be treated, at about the time of awakening. The time-specific controlled release dosage formulation comprises (1) a core including the pharmaceutically active agent(s) effective for the treatment of the early morning pathology, and (2) a swellable polymeric coating layer substantially surrounding the core. The swellable polymeric coating layer delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer, to effect delivery of the pharmaceutically active agent at about the time of awakening.